The DIPCOVAN kit was developed indigenously by the scientists, followed by extensive validation on more than 1,000 patient samples at various COVID designated hospitals in Delhi. Three batches of the product were validated during last one year. The antibody detection kit is approved by Indian Council of Medical Research (ICMR) in April 2021.
Exhaled Breath may Soon Help in Detecting Bacteria that Infect the Stomach: Research
In May 2021, the product received the regulatory approval from the Drugs Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare, to manufacture for sale and distribution.
DIPCOVAN is intended for the qualitative detection of IgG antibodies in human serum or plasma, targeting SARS-CoV-2 related antigens. It offers a significantly faster turn-around-time as it requires just 75 minutes to conduct the test without any cross reactivity with other diseases. The kit has a shelf life of 18 months.
Is Your Tea safe in Paper Cup: IIT Scientists Proves Existence of Micro-plastic Pollution in it
Industry partner Vanguard Diagnostics Pvt. Ltd will commercially launch the product during the first week of June 2021. Readily available stock at the time of launch will be 100 kits (approx. 10,000 tests) with a production capacity of 500 kits/month after the launch. It is expected to be available at about Rs 75 per test.
The kit will be very useful for understanding COVID‐19 epidemiology and assessing an individual's previous SARS‐CoV‐2 exposure.
Raksha Mantri Rajnath Singh has appreciated the efforts of DRDO and the industry in developing the kit at the time of need.
Stressful Circumstance: Know How to Safeguard your Physical, Mental and Emotional Health
Secretary Department of Defence R&D & Chairman DRDO Dr G Satheesh Reddy complimented the teams involved in developing the kit and said the initiative will help the people during the pandemic. (Source PIB)
Post a Comment